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Abstract
Background: Vessel-sparing anastomotic repair (vsAR) has been developed as a less traumatic alternative to
transecting anastomotic repair (tAR) to treat isolated short bulbar urethral strictures. This vessel-sparing technique
could result in improved functional outcomes without jeopardizing the excellent surgical outcome after
(transecting) anastomotic repair. The purpose of this study is to directly compare vsAR and tAR for both surgical
and functional outcomes.
Methods: This trial is a prospective, interventional, multi-center, single-blinded, 1:1 randomized, controlled, non-
inferiority, phase II trial. Sample size calculation resulted in a required sample size of 100 patients (50 patients per
arm). Trial participants will be randomized by an independent third party using a computer-based random
sequence generator with permuted blocks of variable size. The primary objective of this trial is to show that vsAR is
non-inferior to tAR in terms of failure-free survival after 24 months of follow-up, considering a non-inferiority limit of
10%. Failure is defined as the inability to pass a 16-Fr flexible cystoscope through the reconstructed area without
damaging the urethral mucosa. Secondary end-points mainly include differences in postoperative complications
and changes in functional outcome parameters, which will be assessed with validated questionnaires. All
participants are scheduled for follow-up at 3, 12, and 24 months postoperatively.
Discussion: This trial will provide level Ib evidence about the differences in both surgical and functional outcome
between vsAR and tAR, which may importantly scape the future of bulbar urethral reconstruction. Depending on the
trial results, this phase II trial may generate a larger phase III trial with more statistical power and a lower alpha value.
Trial registration: This trial is registered at clinicaltrials.gov (NCT03572348) and in the Belgian Clinical Trial Registry
(B670201837335). The trial was registered prospectively. Registered on 28 June 2018.
Keywords: Urethral stricture, Urethroplasty, Anastomotic repair, End-to-end, Excision and primary anastomosis, Vessel-
sparing, Non-transecting, Transecting, Randomized controlled trial
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Introduction
Background and rationale {6a}
Urethral stricture disease is a common urological
condition in men. Although rigorous epidemiologic data
are sparse, the existing papers report an incidence
varying between 0.6 and 1.4% [1]. Urethral strictures can
occur throughout the entire length of the urethra, but
mainly involve the anterior urethra and in particular the
bulbar segment [2].
The International Consultation on Urologic Diseases
(ICUD) recommends anastomotic repair (AR)
urethroplasty for isolated short bulbar urethral strictures
[3]. This approach, in which the diseased bulbar urethral
segment is excised and an end-to-end anastomosis is
performed, is an optimal choice for strictures up to 3 cm
and provides a composite success rate of 93.8% [3].
Traditionally, AR urethroplasty involved full thickness
transection of the corpus spongiosum and the embedded
urethral blood supply. However, it is only required to excise
the narrow segment of the urethra and the surrounding
spongiofibrosis, and therefore, a full thickness transection
of the corpus spongiosum is in fact unnecessary. Against
this background, Jordan et al. published an alternative,
vessel-sparing technique in 2007 [4, 5], and since
then, several urethroplasty centers have implemented
this technique in their surgical repertoire [6–10]. It
should be noted though that in some of these centers
the vessel-sparing technique does not involve an ac-
tive dissection and isolation of the bulbar arteries at
the bulb of the corpus spongiosum, in contrast to
Jordan et al., as this dissection is in fact unnecessary,
time-consuming, and more traumatizing [6, 7].
Anyhow, the act of leaving the bulbar arteries intact in
vessel-sparing anastomotic repair (vsAR) could offer certain
functional benefits compared to the classic transecting
anastomotic repair (tAR) technique. Preserving the bulbar
arteries potentially reduces the risk of postoperative erectile
dysfunction or glans ischemia, and it could be beneficial for
subsequent interventions of the urethra; a free graft
urethroplasty for instance, in which a rich vascular bed is
essential; or the implantation of an artificial urinary
sphincter, in which a well-sustained vascularization is im-
perative for success [4–7]. However, prospective studies
comparing the functional outcome of both techniques with
validated questionnaires are currently lacking, and thus,
these potential benefits remain mere theoretical
assumptions.
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Be that as it may and potential functional benefits
aside, vsAR should at least be able to provide a
comparable (or non-inferior) surgical success rate as the
transecting technique to be considered a truly valuable
alternative. Promising short-term results have been de-
scribed in single-arm observational studies and are in
line with the reported composite success rate of the
ICUD [3, 6–10]. However, direct comparisons between
vsAR and tAR have only been done in retrospective
studies which are strongly biased by the fact that pa-
tients who underwent vsAR had shorter follow-up than
patients who underwent tAR [11, 12]. Moreover, since
vsAR is a more novel technique, one could hypothesize
that the performing surgeon is better trained and more
experienced in the era of vsAR compared to the earlier
in their surgical career, when tAR was the only AR
technique.
Considering the above, the aim of this randomized
controlled trial is to directly compare vsAR and tAR for
both surgical and functional outcomes.
Objectives {7}
The primary objective of this trial is to show that
failure-free survival (FFS) after vsAR is non-inferior to
tAR after 24 months of follow-up.
❖ Failure is defined as the inability to pass a 16-Fr
flexible cystoscope through the reconstructed area with-
out damaging the urethral mucosa.
❖ The non-inferiority limit, d, was set at 10%. This
non-inferiority limit was chosen based on experts’ opin-
ion, 5 patients’ opinion, and a round-the-table consensus
discussion.
❖ The fact that failure after AR usually occurs
within the first years after surgery serves as the
rationale behind the follow-up interval of 24 months
in this study [13].
Main research question, study hypothesis (Ha), and
null hypothesis (H0) based on primary objective:
– Is the FFS after vsAR not inferior to the FFS after
tAR in isolated short bulbar urethral strictures?
– Study hypothesis (Ha): The FFS after vsAR is not
inferior to the FFS after tAR in isolated short bulbar
urethral strictures.
– Null hypothesis (H0): The FFS after vsAR is inferior
to the FFS after tAR in isolated short bulbar urethral
strictures.
Trial design {8}
This trial is a prospective, interventional, multi-center,
single-blinded, 1:1 randomized, controlled, non-inferiority,
phase II trial.
Methods: participants, interventions, and outcomes
Study setting {9}
This international multi-center trial will be deployed in
the following centers (referral centers for management
of urethral stricture disease):
1. Department of Urology, Ghent University Hospital,
C. Heymanslaan 10, 9000 Ghent, Belgium
2. Department of Urology, Hospital San José
Tecnológico de Monterrey, Universidad de Monterrey,
Nuevo León, Mexico (Local PI & correspondent:
Oscar Arturo Suárez Fernández de Lara)
3. Department of Urology, Hospital de Santa María,
Universidad de Lisboa, Lisboa, Portugal (Local PI &
correspondent: Francisco Martins)
4. Department of Urology, Hospital Italiano de Buenos
Aires, Buenos Aires, Argentina (Local PI &
correspondent: Carlos Giudice)
5. Department of Urology, Eastern Virginia Medical
School, Norfolk, VA, USA (Local PI &
correspondent: Ramon Virasoro)
6. Centro de Uretra Las Alamedas, Mexico (Local PI
& correspondent: Erick Ramirez)
7. Department of Urology, SUNY Upstate Medical
University, Syracuse, NY, USA (Local PI &
correspondent: Dmitriy Nikolavsky)
8. Department of Urology, University Hospital
Leuven, Leuven, Belgium (Local PI &
correspondent: Steven Joniau)
9. Department of Urology, Hospital Univ. Marqués de
Valdecilla, Santander, Spain (Local PI and
correspondent: Félix Campos)
10. Department of Urology, Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital, 200233 Shanghai,
China (Local PI and correspondent: Lujie Song)
11. Department of Urology, University College London
Hospital, London, UK (Local PI and correspondent:
Tamsin Greenwell)
12. Department of Urology, Shaare Zedek Medical
Center, Jerusalem, Israel (Local PI and
correspondent: Ofer Shenfeld)
13. Department of Urology, Beijing Jishuitan Hospital,
Beijing, China (Local PI and correspondent: Jianwei
Wang)
14. Department of Urology, University Hospital of
Liège, Liège, Belgium (Local PI and correspondent:
Maxime Sempels)
Eligibility criteria {10}
Inclusion criteria for participants:
– Voluntarily signed written informed consent
according to the rules of ICH-GCP (Declaration of
Helsinki) and national regulations.
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– Age ≥ 18 years.
– Male patient.
– Fit for operation, based on the surgeon’s expert
opinion.
– Isolated short (≤ 3 cm) bulbar urethral stricture
confirmed by imaging. Imaging includes at least
retrograde urethrography (RUG). In case of
equivocal findings, voiding cysto-urethrography
(VCUG) and urethroscopy must be added.
– Patient is able and willing to comply with the
postoperative protocol.
Exclusion criteria for participants:
– Absence of signed written informed consent.
– Age < 18 years.
– Female patients.
– Transgender patients.
– Patients unfit for operation.
– Concomitant urethral strictures at other urethral
locations (penile urethra, membranous urethra,
prostatic urethra, bladder neck).
– Urethral strictures > 3 cm.
– Urethral stricture(s) at other urethral locations
(penile urethra, membranous urethra, prostatic
urethra, bladder neck).
– Lichen sclerosus-related strictures.
– Strictures after failed hypospadias repair.
– Patients with neurogenic bladder.
– Shift of technique to augmented urethroplasty or
any technique other than AR due to any
circumstance. These patients will be logged, but will
be excluded (post-hoc) from further analysis within
this trial.
– History of pelvic radiation therapy.
– Active treatment to enhance erectile function (such
as PDE5-inhibitors and intracavernous injections) at
the moment of prescreening for inclusion in this trial.
– Any condition or situation, which, in the
investigator’s opinion, puts the patient at significant
risk, could confound the study results, or may
interfere significantly with the patient’s participation
in the study.
– Patient declares that it will be impossible for him to
attend the follow-up consultations.
Eligibility criteria for participating centers:
Only urethral surgeons who state that they are
sufficiently capable of performing both vsAR and tAR
are allowed to participate in this trial.
Who will take informed consent? {26a}
Patients meeting the in- and exclusion criteria of this
trial will be thoroughly informed about this trial by the
local principal investigator (PI) and will be asked if they
are willing to participate. If so, the local PI will ask the
patient to sign the written informed consent form. All
informed consent forms will be stored in a locked file
cabinet, unavailable to anyone except the local PI.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Not applicable as no biological specimens will be
collected as part of this trial.
Interventions
Explanation for the choice of comparators {6b}
The comparator, tAR, has been the gold standard
technique for as long as anastomotic repairs exist [3]. In
2007, vsAR was invented as a less traumatic variant of
the classic tAR, hoping to optimize functional outcome
after this procedure without jeopardizing the excellent
FFS rates after this type of surgery [4, 5].
Intervention description {11a}
All patients will be asked to sign the written informed
consent form at the beginning of the study, and once
signed, they will be asked to fill in the preoperative
questionnaire.
Preoperatively, all patients will be asked to deliver a
urine sample for urinalysis and urine culture. Patients
with evidence of a urinary tract infection will be treated
with adequate antibiotics according to the participating
center’s standard of care.
The same routine perioperative care will be applied to
patients of both groups.
Surgical approach will be different for patients of
different groups:
– Main steps in vsAR involve: midline perineal skin
incision, cleavage of the bulbospongious muscle,
circumferential dissection of the bulbar urethra,
mobilization of the urethra by freeing it
circumferentially from the penoscrotal angle up to
the urogenital diaphragm, dorsal longitudinal
urethrotomy over the strictured area, resection of
the urethral stricture and surrounding
spongiofibrosis, dorsal spatulation of the healthy
urethral ends, transverse closure of the urethra over
a catheter, spongioplasty, closure of the
bulbospongious muscle, and closure of the wound in
multiple layers [14].
– Main steps in tAR involve: midline perineal skin
incision, cleavage of the bulbospongious muscle,
circumferential dissection of the bulbar urethra,
mobilization of the urethra by freeing it
circumferentially from the penoscrotal angle up to
the urogenital diaphragm, resecting the entire
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urethral segment (with its surrounding corpus
spongiosum) that is strictured, spatulation of the
healthy urethral ends, transverse closure of the
urethra over a catheter, spongioplasty, closure of the
bulbospongious muscle and closure of the wound in
multiple layers.
As mentioned above, routine postoperative care will
be provided to all patients and will be similar for
patients of both groups.
A voiding cysto-urethrography (VCUG) will be per-
formed 10–14 days after surgery, and in case of no or in-
significant contrast leakage, the transurethral catheter
will be removed. In case of significant contrast extrava-
sation, the catheter will be maintained and imaging will
be repeated 1 week later until no more significant con-
trast leakage can be identified. This short-term imaging
will be similar for patients of both groups.
Follow-up moments will be held at 3, 12, and 24months
postoperatively and will involve urethroscopy, filling in the
postoperative questionnaire and uroflowmetry. Follow-up
will be similar for patients of both groups.
Criteria for discontinuing or modifying allocated
interventions {11b}
Conversion of vsAR to tAR for any reason is allowed
upon the operating surgeon’s discretion. These patients
will be considered part of the vsAR group in the
intention-to-treat (ITT) analyses and will be considered
part of the tAR group in the per-protocol (PP) analyses.
All shifts of technique towards augmented urethroplasty
or any technique other than AR due to any circumstance
will be logged, but these patients will be excluded (post-
hoc) from further analysis within this trial.
Strategies to improve adherence to interventions {11c}
No specific strategies to improve adherence to interventions
are foreseen.
Relevant concomitant care permitted or prohibited
during the trial {11d}
No concomitant care will be prohibited during the trial.
Provisions for post-trial care {30}
A no-fault insurance is foreseen for all trial participants.
Outcomes {12}
Primary end-point
– To show that FFS after vsAR is non-inferior to tAR
after 24 months of follow-up.
❖ Failure is defined as the inability to pass a 16-Fr
flexible cystoscope through the reconstructed area
without damaging the urethral mucosa. This ana-
tomical definition of failure was chosen based on the
fact that it has—to the best of our knowledge—the
highest sensitivity and specificity to detect stricture re-
currence after urethroplasty. In our opinion, this end-
point leaves little to no room for interpretation,
whereas a functional definition of failure (“need for re-
intervention”) might be strongly influenced by the
treating physician (e.g., physicians who personally favor
technique A over B might be more reluctant to offer
redo surgery to this group compared to patients treated
with technique B, thus introducing the biased result
that A would be better than B because fewer patients
have to be re-operated during the follow-up period).
❖ The non-inferiority limit, d, was set at 10%. This
non-inferiority limit was chosen based on experts’
opinion, 5 patients’ opinion and a round-the-table
consensus discussion.
❖ The fact that failure after AR usually occurs
within the first years after surgery serves as the
rationale behind the follow-up interval of 24 months
in this study [13].
Secondary end-points
– To analyze change in erectile function and
differences in change of erectile function between
vsAR and tAR.
❖ The International Index of Erectile Function
(IIEF-5) questionnaire* will be administered to
participants preoperatively and after 3, 12, and 24
months of follow-up.
❖ The IIEF-5 questionnaire provides a summative
score between 5 and 25 and should be interpreted as
follows: 22–25 = no erectile dysfunction; 17–21 =
mild erectile dysfunction; 12–16 =mild to moderate
erectile dysfunction; 8–11 =moderate erectile dys-
function; 5–7 = severe erectile dysfunction.
❖ De novo postoperative worsening of erectile
function will be defined as a decrease of ≥ 5 points
on the postoperative IIEF-5 questionnaire compared
to the preoperative IIEF-5 questionnaire. This defin-
ition was chosen based on experts’ opinion, taking
into account the lack of studies describing the ideal
cut-off value to delineate “de novo erectile dysfunc-
tion” for this 5-item questionnaire [12].
To analyze change in ejaculatory function and
differences in change of ejaculatory function between
vsAR and tAR.
❖ The Male Sexual Health Questionnaire—
Ejaculatory Dysfunction short form (MSHQ-EjD
short form) questionnaire** will be administered to
participants preoperatively and after 3, 12, and 24
months of follow-up.
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❖ The MSHQ-EjD short form questionnaire, con-
sisting of 4 questions, provides a summative score
between 1 and 15 (question 1–3) and a bother/satis-
faction score between 0 and 5 (question 4).
To analyze change in lower urinary tract symptoms
(LUTS) and differences in change of LUTS between
vsAR and tAR.
❖ The International Consultation on Incontinence
Questionnaire—Male Lower Urinary Tract Symptoms
module (ICIQ-MLUTS module) questionnaire** will
be administered to participants preoperatively and
after 3, 12, and 24months of follow-up.
❖ The ICIQ-MLUTS module, consisting of 7 ques-
tions, provides a summative score between 0
(asymptomatic) and 24 (most symptomatic) (ques-
tion 1–6) and a bother score between 0 (not bother-
some) and 3 (very bothersome) (question 7).
❖ Remark: The 7 questions of the ICIQ-MLUTS
module questionnaire are only a subset of the entire
ICIQ-MLUTS questionnaire. These 7 questions were
chosen because of their relevance in a setting of ur-
ethral stricture disease and were validated in English,
Dutch, and other languages (cfr. infra).
❖ Peeling’s voiding picture** will be administered to
participants preoperatively and after 3, 12, and 24
months of follow-up.
❖ Peeling’s voiding picture provides a score between
1 and 4.
– To analyze change in urinary incontinence and
differences in change of urinary incontinence
between vsAR and tAR.
❖ The International Consultation on Incontinence
Questionnaire—Urinary Incontinence short form
(ICIQ-UI short form) questionnaire will be
administered to participants preoperatively and after
3, 12, and 24 months of follow-up.
❖ The ICIQ-UI short form questionnaire, consisting
of 3 scoring questions and 1 self-diagnostic question,
provides a summative score between 0 (asymptom-
atic) and 21 (most symptomatic).
– To analyze change in quality of life and differences
in change of quality of life between vsAR and tAR.
❖ The EQ-5D-3L questionnaire** will be adminis-
tered to participants preoperatively and after 3, 12,
and 24 months of follow-up.
❖ The EQ-5D-3L module, consisting of 5 questions,
provides a 5-digit score in which every digit varies
between 1, 2, and 3.
❖ The EQ—Visual Analogue Scale (EQ-VAS)** will
be administered to participants preoperatively and
after 3, 12, and 24 months of follow-up.
❖ The EQ-VAS provides a scale between 0 and 100.
– To analyze patient satisfaction and differences in
patients’ satisfaction between vsAR and tAR.
❖ Two specific questions regarding patient
satisfaction will be asked at 3, 12, and 24months.
– To analyze change in maximum flow rate (Qmax)
and differences in Qmax between vsAR and tAR.
❖ Uroflowmetry will be performed preoperatively
and after 3, 12 and 24months of follow-up.
– To analyze postoperative (< 90 days) complication
rate and differences in postoperative (< 90 days)
complication rate between vsAR and tAR.
❖ Complications within the first 90 postoperative
days will be categorized according to the Clavien-
Dindo classification system [15, 16].
* The IIEF-5 questionnaire is a validated tool to assess
erectile function and can be used in patients undergoing
urethroplasty [17, 18].
** These subsets of questions were validated in English
and in Dutch in a setting of patients with urethral
strictures undergoing urethroplasty [19, 20].
Participant timeline {13}
Timeline VeSpAR trial is shown in Fig. 1.
Sample size {14}
Power analysis and sample size calculation for this non-
inferiority trial were performed using an online software
package:
Sealed Envelope Ltd. 2012. Power calculator for binary
outcome non-inferiority trial. [Online] Available from:
https://www.sealedenvelope.com/power/binary-noninfer-
ior/ [Accessed Mon Apr 162,018].
Different scenarios were simulated, of which the
results are discussed below. In all scenarios, 10% was
considered the non-inferiority limit, d, as mentioned
above.
- Scenario 1: power 0.80; estimated success in control
group (tAR): 95.4%; estimated success in experimental
group (vsAR): 95.3%; for different one-sided alphas:
❖ Alpha 0.025: 72 patients per arm
❖ Alpha 0.05: 56 patients per arm
❖ Alpha 0.10: 41 patients per arm
- Scenario 2: power 0.80; estimated success in control
group (tAR): 95.4%; estimated success in experimental
group (vsAR): 95.4%; for different one-sided alphas:
❖ Alpha 0.025: 69 patients per arm
❖ Alpha 0.05: 55 patients per arm
❖ Alpha 0.10: 40 patients per arm
- Scenario 3: power 0.80; estimated success in control
group (tAR): 97.4%; estimated success in experimental
group (vsAR): 93%; for different one-sided alphas:
❖ Alpha 0.025: 227 patients per arm
❖ Alpha 0.05: 179 patients per arm
❖ Alpha 0.10: 131 patients per arm
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The numbers that were put in the above simulations
are based on an in-home analysis of patients who under-
went anastomotic repair at Ghent University Hospital
between 2000 and 2017. Herein the FFS at 24 months
for vsAR and tAR were 95.3% (standard deviation (SD),
2.3%) and 95.4% (SD, 2.0%) respectively. These exact re-
sults are represented in scenario 1. Scenario 2 represents
a situation in which the surgical outcome would be
exactly the same for vsAR and tAR. Scenario 3 repre-
sents a less favorable situation in which vsAR has a 24
m-FFS of 93% (95.3% − SD) and tAR has a 24m-FFS of
97.4 (95.4% + SD).
In every scenario, the power was set at 0.80, according
to the guidelines for designing a phase II trial [21]. The
results for different alphas are displayed above. Usually,
a non-inferiority trial demands a significance level, alpha,
of 0.025 as these trials only look at one boundary of the
classic two-sided 95% confidence interval (CI) [22].
However, these conditions often lead to (sometimes un-
reasonably) high sample size calculations requiring ex-
cessive financing and recruitment. As a solution,
researchers often design a phase II trial that allows for
more coincidence and thus a trial with a higher signifi-
cance level, alpha. Rubinstein et al. reported alpha values
of 0.10 and 0.20 to be allowed in a phase II trial [21].
Considering the fact that a non-inferiority trial relies on
one-sided testing, we believe a one-sided significance
level, alpha, of 0.10 is allowed and most feasible.
Considering all of the above, a scenario in which the
power is set at 0.80, the one-sided significance level,
alpha, is set at 0.10, the estimated success in control
group is set at 95.4%, and the estimated success in ex-
perimental group is set at 95.3% was found most realistic
and feasible. Considering this and accounting for a
realistic drop-out of 20% (experience based), it was esti-
mated that each arm has to consist of 50 patients, result-
ing in a total sample size of 100 patients.
Recruitment {15}
All patients meeting the inclusion criteria of the trial
and presenting at one of the participating centers will be
informed about the trial and will be asked to participate
(Fig. 2).
Strategies for achieving adequate participant enrolment
in this trial include:
– Repetitive review of the recruitment status (overall
and per participating center) every 3 months.
– Informing local PIs about their recruitment status
and how this relates to other study sites.
The recruitment period is estimated to end in January
2021.
Assignment of interventions: allocation
Sequence generation {16a}
Random allocation of patients to one of both treatment
arms will occur through a computer-based random se-
quence generator with permuted blocks of variable size.
Randomization will be stratified by participating center.
Concealment mechanism {16b}
Random allocation of patients to one of both treatment
arms will be done by a third party who is further not
involved in any process of the trial. When a participating
center other than Ghent University Hospital wants to
allocate a patient to one of both treatment arms, the
local PI will contact the third party for randomization
Fig. 1 Timeline VeSpAR trial. VCUG, voiding cysto-urethrography
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within 1 week before the planned operation (by central
telephone number or e-mail address) and will ask to
which treatment arm “patient X who is going to be oper-
ated on dd/mm/yyyy” is allocated. Note that there will
be no communication of names, initials, or birth dates of
patients; only pseudonymized data will be transferred.
After receival of this request for randomization of a pa-
tient, the third party for randomization will assign a
unique trial identifier to the patient at hand and will re-
spond to which treatment arm this patient has been
allocated.
As such, the randomization process is concealed for the
treating surgeon up until 1 week before surgery. Since these
two different techniques may entail different operating
room preparations (different retractors, different sutures,
etc.), randomization concealment for the treating surgeon
is lifted 1 week preoperatively for logistic considerations.
Implementation {16c}
Random allocation of patients to one of the treatment
arms will be done by a third party who is not involved in
any of the trial procedures.
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT -t1 0
T10-
14d
T3m T12m T24m etc. T24m
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
vsAR X
tAR X
ASSESSMENTS:
Smoking status
X
Presence of
diabetes
X
Cardiovascular
comorbidity
X
Stricture etiology
X
Stricture length
X
Prior urethral
interventions
X
Presence of
suprapubic
catheter
X
Urinary tract
infection
X
Questionnaire
X X X X X
Uroflowmetry
X X X X X
Extravasation on
first postoperative
VCUG
X
Failure on
urethroscopy
X X X X
Fig. 2 SPIRIT figure for enrolment, interventions, and assessments. vsAR, vessel-sparing anastomotic repair; tAR, transecting anastomotic repair;
VCUG, voiding cysto-urethrography
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Patients will be enrolled in the trial by the local PIs,
and after communicating the pseudonymized data of a
new trial participant, the third party for randomization
will assign the participant at hand to one of both
treatment arms (cfr. supra).
Assignment of interventions: blinding
Who will be blinded {17a}
Trial participants will be blinded and, as mentioned
above, randomization of patients will be concealed for
the treating surgeon up until 1 week preoperatively.
Blinding of outcome assessors and data analysts was
considered, but we decided against this due to practical
considerations.
Procedure for unblinding if needed {17b}
Upon patient’s request, unblinding is allowed after
termination of the trial.
In case of any unforeseen medical emergency
requiring unblinding of the trial participant, unblinding
will be allowed as well.
Unblinding will occur through face-to-face contact be-
tween the trial participant and the local PI who may then
reveal the exact surgical technique that was performed.
Data collection and management
Plans for assessment and collection of outcomes {18a}
FFS after 3, 12, and 24months will be assessed by
urethroscopy using a flexible 16-Fr cystoscope. Not be-
ing able to pass this flexible cystoscope past the area of
reconstruction will be logged as a failure.
Changes in functional outcome 3, 12, and 24months
after the operation will be assessed with validated
questionnaires, as mentioned above. The scores on these
questionnaires will be compared with the baseline
questionnaire every patient has to fill in preoperatively.
A short list of these questionnaires can be found
hereafter:
– Change in erectile function: IIEF-5 questionnaire
– Change in ejaculatory function: MSHQ-EjD short
form questionnaire
– Change in LUTS: ICIQ-MLUTS module and Peel-
ing’s voiding picture
– Change in urinary incontinence: ICIQ-UI short form
questionnaire
– Change in quality of life: EQ-5D-3L questionnaire
and EQ-VAS
– Postoperative patient satisfaction: 2 separate
questions.
Change in Qmax will be assessed by uroflowmetry at
3, 12, and 24 months postoperatively and will be
compared to the preoperative Qmax.
Postoperative complications will be assessed by the
treating surgeon through thorough history taking and
physical examination at the 3-month follow-up moment.
Surgical complications will be logged and categorized ac-
cording to the Clavien-Dindo classification system [15, 16].
Every local PI of every participating center will receive
an electronic document stipulating how to assess the
aforementioned outcome variables and how to enter
these data in the online data registry (cr. infra). The
follow-up of patients within this trial is comparable to
the follow-up of urethroplasty patients outside the con-
text of a clinical trial, and therefore, no specific training
for outcome assessors is foreseen.
Plans to promote participant retention and complete
follow-up {18b}
Participant retention will be promoted by scheduling
every foreseen follow-up moment (10 days, 3 months, 12
months, and 24 months postoperatively) in advance,
ideally at the moment of inclusion or at the moment of
discharge from the hospital. If patients do not show up
at the foreseen follow-up moment and do not resched-
ule, they will be invited for a new appointment by tele-
phone or e-mail.
Data management {19}
The local PIs of the participating centers will enter all
required data individually in a firewall protected online
data registry which complies with the guidelines of good
clinical practice. Access to this online data registry is
only possible upon invitation by the central PI or the
trial coordinator and by use of a unique, center-specific
password. All data will be stored in a central IBM SPSS
database which is protected by an institutional firewall
system. All data, entered and stored, will be pseudony-
mized to comply with current privacy regulations. Local
PIs will have access to the data of their own patients en-
rolled in this trial. The central PI and the trial coordin-
ator will have access to all data. Before the start of
recruitment, every local PI of every participating center
will receive an electronic document including a list of
variables that will be collected and thorough instructions
on how to enter data. A manual bimonthly data check
will be performed by the trial coordinator to optimize
data quality.
Confidentiality {27}
Data entry and communication about trial participants
will be pseudonymized to guarantee confidentiality,
before, during, and after the trial. Pseudonymized
patient data will only be accessible for members of the
research team.
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Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Not applicable as no biological specimens will be
collected as part of this trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
ITT analyses will be used for all end-points.
Analysis of the primary end-point
Kaplan-Meier curves for FFS will be plotted with the
corresponding log-log 80% CIs for vsAR and tAR.
Non-inferiority of vsAR versus tAR in terms of FFS at
24 months will be concluded when the lower limit of the
80% CI for the difference in FFS probability at 24
months does not exceed − 10%. Note that this analysis
does not take into account the nesting of patients within
centers, which may affect the estimated standard errors.
To take into account the clustering of patients within
centers, a marginal Cox proportional hazards model can
be fitted (using the cluster function from the “survival”
package in R software) which will give a robust
estimation of the variance. The lower limit of the 80%
CI for the hazard ratio can be transformed into a limit
of survival difference at 24 months, assuming an
exponential distribution of failure-free survival times
[S(t) = exp.{−λt}].
Analysis of the secondary end-points
Postoperative changes in erectile function, ejaculatory
function, LUTS, urinary incontinence, and quality of life
will be analyzed by comparing the scores of the
postoperative questionnaires with the scores of the
preoperative questionnaires. For every participant, the
3-, 12-, and 24-month follow-up questionnaire scores
will be compared to the respective preoperative ques-
tionnaire scores. Differences in scores will be logged for
the 3-, 12-, and 24-month follow-up moment, and for
each of these time-points, the median (interquartile
range (IQR)) change in scores will be assessed for vsAR
and tAR. Median (IQR) change in scores will be com-
pared between vsAR and tAR using a two-sided Mann-
Whitney U test at the 20% significance level.
As regards de novo postoperative worsening of erectile
function, defined as a decrease of ≥ 5 points on the
postoperative IIEF-5 questionnaire compared to the pre-
operative IIEF-5 questionnaire, a two-sided Fisher’s exact
test at the 20% significance level will be used to compare
vsAR and tAR at the 3-, 12-, and 24-month follow-up
moment.
Postoperative patient satisfaction will be assessed at
the 3-, 12-, and 24-month follow-up moment. For each
time-point, the proportion of satisfied patients will be
compared between vsAR and tAR using a two-sided
Fisher’s exact test at the 20% significance level.
Postoperative change in Qmax will be compared
between vsAR and tAR at the 3-, 12-, and 24-month
follow-up moment using a two-sided Mann-Whitney U
test at the 20% significance level.
Postoperative complications will be compared between
vsAR and tAR using a two-sided Fisher-Freeman-Halton
test at the 20% significance level.
Note that for all secondary end-points, participants
will be censored at the moment they undergo a subse-
quent urethral treatment (dilation, urethrotomy, ure-
throplasty, or urinary diversion).
Interim analyses {21b}
A formal interim analysis for safety is planned when the
3-month follow-up data of the first 50 randomized pa-
tients are obtained. This analysis will be performed by
the independent third party for safety and the trial co-
ordinator. The following stop criteria have been
predefined:
– 3 m-FFS of vsAR and its two-sided 95% CI are en-
tirely beneath the 3 m-FFS of tAR – 10%.
– > 30% difference between vsAR and tAR in de novo
postoperative worsening of erectile function, defined
as a decrease of ≥ 5 points on the postoperative
IIEF-5 questionnaire compared to the preoperative
IIEF-5 questionnaire.
If one of the stop criteria is reached, the independent
third party for safety will discuss this with the central PI
and the central Ethical Committee, and a decision about
prematurely stopping the trial will be formulated and
communicated to all parties involved in the trial.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
Interaction tests for FFS were considered for traumatic
versus non-traumatic stricture etiology and for primary
versus secondary procedures. However, the rule of
thumb says that at least 10 failures are needed per de-
gree of freedom included in the model. Allowing for a
modification of the effect of procedure by stricture eti-
ology for instance would imply adding 3 degrees of free-
dom to the model (technique, center, and stricture
etiology). This would lead to overfitting, which means
the obtained results might not be reproducible in other
samples. We will refrain from generalizing our findings
from these (over)complex models to the larger popula-
tion of patients and stick to purely descriptive results
when considering more than one explanatory covariate.
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The PP analysis of de novo postoperative worsening of
erectile function after vsAR and tAR will be performed
as well (two-sided Fisher’s exact test at the 20%
significance level) to explore the effect of full-thickness
transection on postoperative erectile function.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Participant retention, protocol adherence, and minimization
of missing data will be promoted by scheduling every
foreseen follow-up moment (10 days, 3months, 12months,
and 24months postoperatively) in advance, ideally at the
moment of inclusion or at the moment of discharge from
the hospital. If patients do not show up at the foreseen
follow-up moment and do not reschedule, they will be in-
vited for a new appointment by telephone or e-mail.
In case of drop-out, patients will be contacted by the
local PI and the reason for drop-out will be logged quali-
tatively. In case of no further contact with the partici-
pant at hand, “unknown reason for drop-out” will be
logged. These participants will be censored at the mo-
ment of latest follow-up.
In case of protocol non-adherence, the reason for this
will be logged qualitatively by the local PI.
Missing or incorrect data will be detected by software
programs and will be reported transparently in the
publication of trial results.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The datasets generated and/or analyzed during the
current study are not publicly available due to the
European Union General Data Protection Regulation,
but are available from the corresponding author on
reasonable request.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
Ghent University Hospital will be the coordinating
center, and the trial steering committee will be
composed as follows:
– Central PI = prof. dr. Nicolaas Lumen
– Trial coordinator = dr. Wesley Verla
– Back-up trial coordinator = dr. Marjan Waterloos
– Central subinvestigators = dr. Wesley Verla, dr.
Marjan Waterloos, dr. Mieke Waterschoot, dr.
Benjamin Van Parys, dr. Anne-Françoise Spinoit
– Independent third party for random allocation of
trial participants to one of both treatment arms.
– Independent third party for data monitoring and
protection of patient safety by analyzing the harm of
both treatment arms.
– An institutional biostatistician.
– An institutional data protection officer will protect
every process of data management and will verify
whether each and every step in this process is
according to current privacy regulations.
– The clinical trials unit of Ghent University
Hospital’s ‘Health, Innovation and Research’
department will oversee trial progress and steer
where necessary.
Composition of the data monitoring committee, its role
and reporting structure {21a}
There will be no formal data monitoring committee
independent from the sponsor or the trial steering
committee. Patient safety will be protected by an
independent third party who will bimonthly assess the
harm of both treatment arms. This independent third
party for safety has no conflict of interest with the
sponsor of this trial. Stop criteria have been predefined
by the trial steering committee (cfr. supra). If one of the
stop criteria is reached, the independent third party for
safety will discuss this with the central PI and the
central Ethical Committee and a decision about
prematurely stopping the trial will be formulated and
communicated to all parties involved in the trial. A
formal interim analysis for safety is planned when the 3-
month follow-up data of the first 50 randomized patients
are obtained.
Adverse event reporting and harms {22}
Adverse events and postoperative complications will be
assessed by the treating surgeon through thorough history
taking, physical examination, or by any means necessary.
If present, these adverse events and postoperative
complications will be logged and categorized according to
the Clavien-Dindo classification system [15, 16]. Treat-
ment of adverse events and postoperative complications
will take place according to the best standard of care of
the participating center at hand.
Frequency and plans for auditing trial conduct {23}
A yearly audit will be organized by the clinical trials unit
of Ghent University Hospital’s “Health, Innovation and
Research” department.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
All important protocol amendments will be communicated
by e-mail to the central Ethical Committee and to all local
PIs, who are in turn responsible to communicate this to
their own local Ethical Committee.
Verla et al. Trials          (2020) 21:782 Page 11 of 13
Dissemination plans {31a}
Trial results will be published in the format of an
original article which will be submitted for peer review
and publication in an A1 journal. Besides, an abstract of
the trial’s results will be submitted for presentation at
national and international scientific meetings. Trial
results will be published irrespective of the direction or
nature of the findings.
Discussion
This study will provide evidence about whether vsAR
yields non-inferior surgical results compared to tAR or
not. This question has been subject to debate for over a
decade, and yet, only retrospective research is available
on this topic. To the best of our knowledge, this trial is
the first randomized controlled trial to address the ques-
tion at hand.
Beside the comparison of surgical outcome after both
techniques, this trial will also investigate differences in
change of functional outcome parameters between both
techniques. This will further elucidate the true value of
bulbar artery preservation and either refute or confirm
the advocated theories about functional benefits.
Depending on the trial results, this phase II trial may
be the basis for a larger phase III trial with more
statistical power and a lower alpha value.
Trial status
The first patient was included on September 29, 2018.
All trial participants are scheduled to be enrolled by
January 2021. The outlined protocol is protocol version
1.2 (November 12, 2019).
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